Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students
Launched by HOPITAL FOCH · Oct 7, 2024
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a talk about the HPV vaccine affects whether teenagers decide to get vaccinated. The study will take place in two towns where some third-grade students will receive information about the importance of the HPV vaccine, while students in two other towns will not have this talk. By comparing these groups, researchers hope to see if the talk encourages more students to get vaccinated.
To participate in this trial, students need to be in the third grade at public secondary schools in Suresnes or Rueil-Malmaison. Students who are absent on the day of the talk or who do not want to fill out a questionnaire will not be included. If your child is eligible, they can expect to learn about the vaccine and share their thoughts through a simple questionnaire afterward. It’s an opportunity to help understand how education about vaccines can influence health choices among young people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 3rd grade students enrolled in public secondary schools in Suresnes and Rueil-Malmaison.
- Exclusion Criteria:
- • Students absent on the day of the talk.
- • Students unwilling/unable to complete questionnaire.
About Hopital Foch
Hospital Foch is a leading healthcare institution located in Suresnes, France, renowned for its commitment to innovative medical research and patient-centered care. As a prominent clinical trial sponsor, Hospital Foch actively engages in the development of new therapeutic approaches across various medical disciplines, facilitating cutting-edge studies that aim to enhance treatment outcomes and improve patient quality of life. With a multidisciplinary team of experienced researchers and healthcare professionals, the hospital fosters a collaborative environment that prioritizes ethical standards and scientific rigor, ensuring the highest quality in clinical trial execution and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported